The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma

Jesse Lopes da Silva¹,² *, Lucas Zanetti de Albuquerque¹, Fabiana Resende Rodrigues³, Guilherme Gomes de Mesquita¹,³, Cláudia Bessa Pereira Chaves¹,², Martín Hernán Bonamino⁴,⁵ and Andreia Cristina de Melo¹

Abstract

Objective: To examine the prevalence and prognostic role of tumor microenvironment (TME) markers in uterine carcinosarcoma (UCS) through immunohistochemical characterization.

Methods: The internal database of our institution was queried out for women with UCS who underwent surgery and thereafter postoperative chemotherapy with carboplatin and paclitaxel between January 2012 and December 2017. Tissue microarrays containing surgical samples of UCS from 57 women were assessed by immunohistochemistry for CD3, CD4, CD8, FOXP3, PD-1, PD-L1, and PD-L2.

Results: The mean age was 65.3 years (range, 49 to 79 years). For the epithelial component (E), CD3_E and CD4_E were highly expressed in 38 (66.7%) and in 40 (70.1%) patients, respectively, and were significantly associated with more advanced stages (p = 0.038 and p = 0.025, respectively). CD8_E was highly expressed in 42 (73.7%) patients, FOXP3_E 16 (28.1%), PD-1_E 27 (47.4%) and PD-L2_E 39 (68.4%). For the sarcomatous component (S), the prevalence of high expression was: CD3_S 6 (10.5%), CD4_S 20 (35.1%), CD8_S 44 (77.2%), FOXP3_S 8 (14%), PD-1_S 14 (24.6%), PD-L1_S 14 (24.6%) and PD-L2_S 8 (14%). By multivariate analysis, the CD8/FOXP3_S ratio (p = 0.026), CD4/E (p = 0.010), PD-L1_E (p = 0.013) and PD-L1_S (p = 0.008) markers significantly influenced progression-free survival. CD4/FOXP3_S ratio (p = 0.043), PD-1_E (p = 0.011), PD-L1_E (p = 0.036) and PD-L1_S (p = 0.028) had a significant association with overall survival.

Conclusion: Some differences in UCS clinical outcomes may be due to the subtype of TILs and PD-1/PD-L1 axis immune checkpoint signaling.

Keywords: Uterine carcinosarcoma, Tumor-infiltrating lymphocyte, Tumor microenvironment, Immune biomarkers, Tumor microenvironment

Introduction

Uterine carcinosarcomas (UCS) are uncommon and overly aggressive tumors with biphasic histology composed of epithelial (E) and sarcomatous (S) elements [1, 2]. Recently, these tumors have been thought to be derived from monoclonal carcinoma cells branched from embryonal mesoderm [3]. Given that, UCS are pointed out as a model for epithelial-mesenchymal transition.
a mechanism that results in loss of cell polarity, adhesion, migratory and invasive properties, which facilitates metastasis [4].

UCS account for less than 5% of uterine cancers and the incidence ranges from 5.1 to 6.9 per 1,000,000 person-years worldwide [5]. This tumor is usually diagnosed in older women, with a median age ranging from 62 to 67 years [6]. African-American women are significantly at more risk of having UCS compared to Caucasian women [7]. In contrast, there is no Brazilian data regarding UCS specifically.

The tumor microenvironment (TME) plays an important role in the progression and metastasis of tumors through the so-called “cancer immunoediting” mechanism that leads to escape of cancer cells from immune surveillance [8]. Several cell types of the innate and adaptive immune system are involved in this complex process, including CD8+ lymphocytes, Th1/Th2 subclasses of CD4+ T lymphocytes, natural killer (NK) cells and forkhead box protein 3 (FOXP3+) T regulatory (Treg) cells [9]. Recently, much has been discussed about the subtyping of tumor-infiltrating lymphocytes (TILs) in neoplasms of different sites [10].

The programmed death 1 receptor (PD-1), found on the surface of activated T cells and many other immune cells, is currently one of the most studied immune regulatory pathways able to strongly influence the mechanism of carcinogenesis, with a great potential of prognostic and therapeutic effect [11]. PD-1 with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), play a crucial role in tumor immune evasion. The immune checkpoint pathways inhibit T cell receptor (TCR) signaling via engagement of SHP-1 and SHP-2 phosphatases, resulting in reduced T-cell proliferation and cytokine production, increasing susceptibility to apoptosis [12]. The Inhibition of the PD-1/PD-L1/PD-L2 interaction by different immunological therapies can cause the T cell function to be restored, providing enhanced anti-tumor immune responses [13].

So far, no effective immune biomarkers have been timely assessed for UCS. This cohort aimed to gain a better insight into the prevalence and prognostic value of TILs subtype, and also PD-1, PD-L1 and PD-L2 expression in patients with UCS.

**Materials and methods**

**Patient selection and data collection**

This study was approved by the Ethics in Human Research Committee of the Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil, and was conducted following the Good Clinical Practice Guidelines. All women diagnosed with UCS, who underwent surgery and thereafter postoperative chemotherapy with the standard dose of every-3-week carboplatin AUC 5 and paclitaxel 175 mg/m² (CP) for six cycles [14] at INCA between January 2012 and December 2017, were identified through the internal database. Patients with a scarce or inadequate pathological sample, with synchronous or anachronistic tumors, were excluded from this cohort. Clinical data regarding sociodemographic factors, staging, surgery, histological subtype (homologous versus heterologous), progression and survival were retrospectively obtained in the medical records. The staging was performed based on the criteria of the International Federation of Gynecology and Obstetrics (FIGO, 2009) [15].

**Immunohistochemistry**

The tissue microarray (TMA) was built using samples of stromal areas of greatest tumor cellularity present in formalin-fixed paraffin-embedded primary tumors in surgical specimens. Three cores were punched in each of the two tumor components (E and S). All immunohistochemistry (IHC) analyses were performed on 4-μm sections following standard procedures. TMA samples were immunostained for CD3 (clone MRQ-39, Cell Marque, diluted 1:1000), CD4 (clone SP35, Cell Marque, diluted 1:400), CD8 (clone SP 16, Cell Marque, diluted 1:1000), FOXP3 (clone 236A/E7, Abcam, diluted 1:50), CD8+ (clone SP142, Ventana, prediluted) and PD-L2 (clone ab200377, Abcam, diluted 1:200). The tumor cell staining was compared with that of negative controls made from counterstaining with hematoxylin and positive controls.

Intratumoral stromal immune markers were manually counted and scored as described hereafter. For PD-L1, PD-L2 and PD-1, the slides were scored according to the percentage of positive immune and tumor cells divided by the number of fields to calculate the mean value for each case, determined at 40x magnification [16]. For TILs subpopulations (CD3+, CD4+, CD8+ and FOXP3+) intratumoral stromal lymphocytes were counted manually and quantified as the average absolute number of immunolabeled lymphocytes at each observed field at 40x magnification [17].

For statistical purposes, the scores of these biomarkers were dichotomized into low and high-level groups for each of the histological elements, E and S, based on cutoff points calculated according to the surv_cutpoint function of the survminer R package [18]. Thus, the cut-off for CD 3_E was 0, CD3_S was 60, CD4_E was 0, CD4_S was 20, CD8_E was 0, CD8_S was 1, FOXP3_E was 0, FOXP3_S was 5, PD-1_E was 0, PD-1_S was 1, PD-L1_E was 1, PD-L1_S was 20, PD-L2_E was 40 and PD-L2_S was 90. Likewise, the cutoff for ratios: CD4/FOXP3_E+ was 1, CD4/FOXP3_S+ was 2, CD8/FOXP3_E+ was 3, CD8/FOXP3_S+ was 3.7, CD8/CD4_E+ was 0.18 and...
CD8/CD4_S+ was 3. The boxplots shown in additional Fig. 1 represent the distributions of the values of markers evaluated. The pathological analysis was performed twice for each slide of TMA by two experienced pathologists.

Statistical analysis
Progression-free survival (PFS) was calculated from the date of first CP infusion to the earliest date of disease progression, recurrence, or death. Overall survival (OS) was calculated from the first CP infusion to the date of death of any cause or censored if the patient was known to be alive on the last day of data collection. The Kaplan-Meier method was used to estimate PFS and OS for each variable. Patients were stratified by age, body mass index (BMI), race, stage, omentectomy, residual disease, adjuvant radiotherapy, lymphovascular invasion (LVI), histological subtype and IHC markers status. All continuous variables were evaluated by the Shapiro-Wilk test of normality. Categorical variables were described by their absolute and relative frequencies.

To assess the association of the IHC markers scores with mean age and BMI, the Student’s t-test was used. The correlation with categorical clinicopathological parameters was performed by Pearson’s chi-squared test and, when applicable, by Fisher’s exact test. A further analysis comparing the paired scores of immunohistochemistry factors for epithelial and sarcomatous components was performed by the Wilcoxon signed-rank test. The crude Hazard Ratio (HR) for each variable was calculated by the Cox proportional hazards. The variables evaluated for survival outcomes on univariate analysis were adjusted for the FIGO stage in multivariate models. A p-value < 0.05 was considered statistically significant. The missing data were excluded from the analysis. The statistical analyses were conducted using the R project version 3.5.3 [18].

Results
The clinicopathological and IHC data of the 57 women included in this cohort were summarized in Tables 1 and 2. The mean age was 65.3 years (range, 49 to 79 years). Briefly, there was a predominance of women ≥60 years old (40 cases, 70.2%), non-Caucasians (42 cases, 75%), with advanced disease (42 cases, 73.7%), heterologous subtype (30 cases, 71.4%), and LVI was detected in 25 cases (60.1%) (additional Table 1). As for treatment data, 37 (65%) patients were submitted to lymphadenectomy, 27 (47.4%) patients underwent omentectomy, optimal debulking (defined as residual disease <1.0 cm) was achieved in 39 (68.4%) and adjuvant radiotherapy was provided to 24 (42.8%) patients (additional Table 2).

By analyzing the E component, CD3_E was highly expressed in 38 (66.7%) patients and significantly associated with more advanced stages (p=0.038). CD4_E was highly expressed in 40 (70.1%) patients and was significantly associated with more advanced stages (p=0.025). CD8_E, FOXP3_E and PD-1_E were at a high level in 42 (73.7%), 16 (28.1%) and 25 (43.9%) patients, respectively, but did not show significant association with any of the clinicopathological features. PD-L1_E was overexpressed in 27 (47.4%) patients and was significantly more highly expressed in patients ≥60 years old (p=0.022) (Table 1). As for the assessment of IHC markers in the S component, the frequencies of highly positive expression were much lower in CD3_S (6 cases, 10.5%) and CD4_S (20 cases, 35.1%). CD8_S was expressed in 44 cases (77.2%), FOXP3_S in 8 cases (14%), PD-1_S in 14 cases (24.6%), PD-L1_S in 14 cases (24.6%) and PD-L2_S in 8 cases (14%) (Table 2). Except for PD-L1, all other TME markers (CD3, CD4, CD8, FOXP3, PD-1 and PD-L2) showed significantly greater expression in the sarcomatous component than in the epithelial component (additional Table 5). Additional Fig. 2 shows representative images of cases with high expression of IHC markers.

With a median follow-up of 51 months (95% confidence interval, CI: 40–70), 42 patients had disease progression or died until the moment of the analysis, and the three-year rate of progression-free survival in the general study population was 21.2% (95% CI: 11.7–38.1). The outcome PFS was compared according to the clinicopathological parameters and IHC evaluations. As stated by the data in Table 3, patients with early stages I/II had 63% lower risk of progression than advanced stages III/IV (Hazard ratio, HR 0.37; 95% CI: 0.16–0.84; p=0.017). By multivariate analysis for PFS, patients with high expression of CD4_E (high vs low; HR 0.43; 95% CI: 0.23–0.82; p=0.010), PD-L1_E (high versus low; HR 0.45; 95% CI: 0.24–0.84; p=0.013) and PD-L1_S (high versus low; HR 0.30; 95% CI: 0.12–0.74; p=0.008) had significantly lower risk of progression or death. Conversely, patients with residual disease after surgery (R1/2 versus R0; HR 3.09; 95% CI: 1.34–7.08; p=0.008) and high CD8/FOXP3_S ratio (high versus low; HR 2.05; 95% CI: 1.08–3.85; p=0.026) significantly yielded poorer OS.

By the moment of the analysis, 38 patients died, and the three-year OS rate was 29.4% (95% CI: 18.1–47.6). As shown in Table 4, patients with early-stage disease I/II had a risk of death 72% lower than advanced stages III/IV (HR 0.28; 95% CI: 0.11–0.71; p=0.008). Regarding multivariate analysis for OS, patients with high expression of PD1_E (high vs low; HR 0.39; 95% CI: 0.19–0.81; p=0.011), PD-L1_E (high versus low; HR 0.49; 95% CI: 0.25–0.96; p=0.037) and PD-L1_S (high versus low; HR 0.37; 95% CI: 0.15–0.90; p=0.028) had significantly lower risk of death. By contrast, there was significantly worse
Table 1  Clinicopathological characteristics of the epithelial component of carcinosarcoma and the status of intratumoral stromal CD3, CD4, CD8, FOXP3, PD-1, PD-L1 and PD-L2 (N = 57)

| Clinicopathological features | Total no. of cases | CD3_E | CD4_E | CD8_E | FOXP3_E | PD-1_E | PD-L1_E | PD-L2_E |
|-----------------------------|--------------------|-------|-------|-------|---------|--------|---------|---------|
|                             |                    | Low   | High  | p-value | Low   | High  | p-value | Low   | High  | p-value | Low   | High  | p-value |
| Age                         |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| < 60                        | 17                 | 6     | 11    | 0.838   | 2     | 15    | 0.052   | 11    | 6     | 0.513   | 7     | 10    | 0.138   |
| ≥ 60                        | 40                 | 13    | 27    |         | 15    | 25    |         | 12    | 28    |         | 30    | 10    |         |
| Stage                       |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| I/II                        | 15                 | 2     | 13    | 0.038   | 2     | 13    | 0.025   | 5     | 10    | 0.584   | 10    | 5     | 0.697   |
| III/IV                      | 42                 | 17    | 25    |         | 15    | 27    |         | 10    | 32    |         | 31    | 11    |         |
| Histological subtype        |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| Heterologous                | 30                 | 9     | 21    | 0.292   | 12    | 18    | 0.277   | 8     | 22    | 0.715   | 23    | 7     | 0.699   |
| Homologous                  | 12                 | 6     | 6     |         | 2     | 10    |         | 4     | 8     |         | 8     | 4     |         |
| LVI/N                       |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| Present                     | 25                 | 4     | 12    | 1.000   | 3     | 13    | 0.712   | 7     | 9     | 0.053   | 12    | 4     | 0.734   |
| Absent                      | 16                 | 6     | 19    |         | 7     | 18    |         | 3     | 22    |         | 17    | 8     |         |

Differences in absolute value correspond to missing data. Significant P-values are emboldened.

LVI: Lymphovascular Invasion, E: Epithelial Component, ER: Estrogen Receptor, PR: Progesterone Receptor, CD3: Cluster of Differentiation 3, CD4: Cluster of Differentiation 4, CD8: Cluster of Differentiation 8, FOXP3: Forkhead Box P3, PD-1: Programmed Cell Death Protein 1, PD-L1: Programmed Death-Ligand 1, PD-L2: Programmed Death-Ligand 2
Table 2  Clinicopathological characteristics of the sarcomatous component of carcinosarcoma and the status of intratumoral stromal CD3, CD4, CD8, FOXP3, PD-1, PD-L1 and PD-L2 (N = 57)

| Clinicopathological features | Total no. of cases | CD3_S | CD4_S | CD8_S | FOXP3_S | PD-1_S | PD-L1_S | PD-L2_S |
|------------------------------|--------------------|-------|-------|-------|---------|--------|---------|---------|
|                              |                    | Low   | High  | p-value | Low   | High  | p-value | Low   | High  | p-value | Low   | High  | p-value |
| Age                          |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| < 60                         | 17                 | 14    | 3     | 0.503   | 8     | 9     | 0.124   | 14    | 3     | 0.795   | 12    | 5     | 0.924   |
| ≥ 60                         | 40                 | 37    | 3     |         | 19    | 11    |         | 35    | 5     |         | 31    | 9     |         |
| Stage                        |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| I/II                         | 15                 | 12    | 3     | 0.367   | 11    | 4     | 0.631   | 5     | 10    | 0.439   | 12    | 3     | 0.732   |
| III/IV                       | 42                 | 39    | 3     |         | 26    | 16    |         | 37    | 5     |         | 33    | 9     |         |
| Histological subtype        |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| Heterologous                 | 30                 | 28    | 2     | 0.909   | 22    | 8     | 0.957   | 7     | 23    | 0.418   | 25    | 5     | 0.834   |
| Homologous                   | 12                 | 12    | 0     |         | 8     | 4     |         | 5     | 7     |         | 11    | 1     |         |
| LVI                          |                    |       |       |         |       |       |         |       |       |         |       |       |         |
| Present                      | 25                 | 21    | 4     | 0.252   | 14    | 11    | 0.625   | 3     | 22    | 0.266   | 20    | 5     | 0.844   |
| Absent                       | 16                 | 16    | 0     |         | 11    | 5     |         | 5     | 11    |         | 14    | 2     |         |

Differences in absolute value correspond to missing data. Significant P-values are emboldened.

LVI  Lymphovascular Invasion, S Sarcomatous Component, ER  Estrogen Receptor, PR  Progesterone Receptor, CD3 Cluster of Differentiation 3, CD4 Cluster of Differentiation 4, CD8 Cluster of Differentiation 8, FOXP3 Forkhead Box P3, PD-1 Programmed Cell Death Protein 1, PD-L1 Programmed Death Ligand 1, PD-L2 Programmed Death Ligand 2
Discussion

Some of the main clinicopathological features of UCS in the current study are in line with previous reports of large cohorts performed by Matsuo et al. through multicenter studies and examining The Surveillance, Epidemiology, and End Results (SEER) program database [19–22]. In this regard, the mean age greater than 60 years and the LVI present in most patients are highlighted. Conversely, advanced-stage disease at diagnosis and heterologous sarcomatous component were more frequent characteristics in this cohort, perhaps due to the delay in diagnosis and local characteristics, respectively.

There is a growing body of evidence supporting the role of TME in the development and growth of solid tumors. Through pro-inflammatory cytokines actively secreted by tumor cells, leukocytes of the innate and adaptive immune system, including macrophages, neutrophils, NK cells, dendritic cells, mast cells, T and B lymphocytes, that infiltrate into the TME [23–26]. Thus, a better understanding of the composition of the
lymphomononuclear infiltrate in TME has paved the way as biomarkers for a more personalized antican-

cer therapy. Many immunotherapeutic agents, includ-
ing immunomodulators, vaccines, adoptive transfer of
endogenous or genetically modified T cells, cytokines,
and mainly immune checkpoint inhibitors (ICIs), have
shown remarkably beneficial effects for better thera-
pic response and increased survival in gynecologic

cancers [27].

To the best of our knowledge, there is no previous
published data assessing the predictive or prognostic
role of TME markers in UCS so far. Likewise, stud-
ies on the characterization of TME in gynecological

cancer are very scarce. Zhang et al. [28] investigated
the prognostic impact of TME profile in 221 patients
with endometrial cancer. Similar to our results, highly
expressed CD4+ TILs were significantly associated
with better OS and longer treatment-free interval and
may be associated with chemosensitivity. Jong et al. [29]
have recently reported 368 FIGO stage I–IV endome-
trial cancer patients with highly expressed CD8+ TILs,
a marker for killer cytotoxic T cells, and a high CD8+/FOXP3+
ratio was associated with better disease-free

survival. FOXP3 is the most specific marker for Treg

cells and, often associated with a negative impact on
survival in several types of cancer, is likely to have an
important role in suppressing anti-tumor immunity [30,
31]. Ore-Arce et al. [32] also reported that high CD8+
TILs was significantly associated with better 5-year OS
in 68 women with FIGO stage I–IV endometrial cancer.

All variables were adjusted for staging in multivariate analysis. Significant P-values are emboldened

LVI Lymphovascular Invasion, E Epithelial Component, S Sarcomatous Component, ER Estrogen Receptor, PR Progesterone Receptor, CD3 Cluster of Differentiation 3, CD4 Cluster of Differentiation 4, CD8 Cluster of Differentiation 8, FOXP3 Forkhead Box P3, PD-1 Programmed Cell Death Protein 1, PD-L1 Programmed Death-Ligand 1, PD-L2 Programmed Death-Ligand 2
Fig. 1 Progression-free survival (PFS) by: A stage; B residual disease status; C CD4_E status; D PD-L1_E status; E PD-L1_S status and F CD8/FOXP3_S ratio status. Residual disease after surgery was stratified into R0 (without residual disease) vs R1 (microscopic residual disease) and R2 (macroscopic residual disease). As for immunohistochemistry markers, Kaplan Meier curves for PFS were stratified by the median values as the cut-off for prognostic evaluation and divided into low vs high lymphocytic variable subsets. The blue solid line indicates patients with low values and the red solid line high values. Tick marks indicate censored data.

Fig. 2 Overall survival (OS) by: A stage; B residual disease status; C PD1_E status; D PD-L1_E status; E PD-L1_S status and F CD8/FOXP3_S ratio status. Residual disease after surgery was stratified into R0 (without residual disease) vs R1 (microscopic residual disease) and R2 (macroscopic residual disease). As for immunohistochemistry markers, Kaplan Meier curves for OS were stratified by the median values as the cut-off for prognostic evaluation and divided into low vs high lymphocytic variable subsets. The blue solid line indicates patients with low values and the red solid line high values. Tick marks indicate censored data.
Conversely, our current results suggested that high CD8/FOXP3_S and CD4/FOXP3_S ratios significantly yielded poorer survival outcomes. Such conflicting findings might be strongly explained by tumor heterogeneity based on the histologic distribution of TILs at the tumor site. The aforementioned studies might have used TMAs that were built up with cores of diverse numbers, sizes and from distinct areas in the surgical samples (peri-tumoral or intra-tumor), consequently with different proportions of other immune cell subtypes that might have important roles in the TME (Myeloid-derived suppressor cells, MDSCs, Macrophages M2, granulocytes, B cells and so on). That said, these other subpopulations of TILs could influence the prognostic impact of the CD8+/FOXP3+ and CD4+/FOXP3+ ratios [33]. Salet and Elkordab [34] have suggested that Treg (FOXP3+) should be performed in subgroups based on their location in the tumor tissue and the current prognostic influence of each subgroup should be evaluated individually.

This cohort also suggested that highly expressed PD-L1, both in the epithelial and sarcomatous components, was found to be significant and independent marker for favorable PFS and OS. Likewise, highly expressed PD-1_E also showed a favorable association with OS in our cohort. PD-1/PD-L1 axis immune checkpoint signaling, known to play an important role in cancer progression and survival, is currently one of the most explored pathways in gynecological cancers [35]. Along with mismatch repair deficiency (dMMR), microsatellite instability (MSI) status and tumor mutational burden (TMB), PD-L1 has been identified as a potential predictive biomarker for endometrial cancer in some phase II clinical trials with immune checkpoint inhibitors [36, 37]. The cohort of 700 patients with uterine cancer performed by Engerud et al. [38] showed PD-L1 and PD-1 expression in 59 and 63% in primary tumors, respectively, with similar expression patterns across microsatellite stable (MSS) and MSI tumors. However, they did not influence survival outcomes.

Some other findings of this cohort suggest that the lymphocyte markers evaluated (CD3, CD4, CD8 and FOXP3), as well as PD-L1, PD-L2 and PD-1, seemed to be more highly expressed amidst the sarcomatous component. Therefore, UCS with sarcomatous dominance (defined as the proportion of the sarcoma component being greater than 50% in the primary tumor within all examined hysterectomy specimens), which was associated with shorter survival in previous reports [20, 21], may be targetable by immunotherapeutic agents. Unfortunately, the analysis of sarcomatous dominance is beyond the scope of the current study. Some data point to the fact that the more advanced the stage of solid tumors, the greater the expression of TILs markers in the TME favoring tumor progression [39].

The survival analyzes further exhibited that advanced stage (III/IV) and incomplete debulking are significantly associated with poorer PFS and OS outcomes. The negative prognostic impact of these clinicopathological variables has already been shown in other cohorts of carcinosarcoma [19, 20, 40, 41]. In a secondary analysis of a prior multicenter retrospective study, Matsuo et al. [42] suggested that LVI containing a sarcomatous component might be a predictor of decreased survival for women with UCS. However, LVI showed no significant association with survival in our cohort.

The strengths of this study lie in the novelty of the in-depth analysis of TME data in UCS by presenting the characteristics of the lymphomononuclear infiltrate correlating with clinicopathological features and evaluating the impact on survival. The study population is homogeneous in that we only included patients with carcinosarcoma who underwent primary surgery and subsequently adjuvant chemotherapy with CP. Moreover, all surgical samples were double-checked by experienced pathologists. Lastly, a thorough descriptive presentation of clinicopathological variables was performed and multivariate analyzes reinforce the internal validity of the results.

The weaknesses of this study are strongly related to the fact that it is a retrospective analysis. So, some missing confounding factors may exist in the analysis. For example, even with well-established institutional protocols, the choice of adjuvant treatment with chemotherapy and or radiotherapy was at the discretion of the care providers. Additionally, the small sample may have been insufficient to ensure adequate power to detect differences in survival for some TME markers. Furthermore, molecular analysis was not performed in this study.

Conclusion
This is possibly the first report to delve into the composition of TME in carcinosarcoma. Assessments of immune markers for progression and survival outcomes may have been impaired by the small sample. However, due to the increased prevalence of high expression of immune markers in this setting, the findings can respectfully provide some basis for formulating studies to evaluate novel therapeutic strategies with immunotherapeutic agents.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-09026-6.

Additional file 1. Table 1. Baseline clinicopathological characteristics of eligible patients (N = 57). Table 2. Treatment data of the study population (N = 57). Table 3. Paired scores of immunohistochemistry markers for epithelial and sarcomatous components analyzed by the Wilcoxon signed-rank test. Table 4. Crude and adjusted Hazards Ratios for Carcinosarcoma progression-free survival (PFS) estimated by univariate analysis and multivariate analysis. Table 5. Crude and adjusted Hazards Ratios for Carcinosarcoma overall survival (OS) estimated by univariate analysis and multivariate analysis. Figure 1. Boxplots representing the distributions of the values of markers. Figure 2. Representative pictures of lymphocyte infiltration in uterine carcinosarcoma showing immunohistochemical staining of high CD3 +, CD4 +, CD8 +, FOXP3 +, PD-1 +, PD-L1 + and PD-L2 +. Original magnification: ×400 (×40 objective).

Acknowledgements

The authors are indebted to all patients and their families for their trust and participation and for the provision of biological material for research purposes. The authors wish to thank Mrs. Isabele Small for technical support with statistical analysis. The authors declare that they have no conflicts of interest.

Authors' contributions

JLS and ACM designed and planned the study. JLS, LZA, FRR and GGM collected and analyzed clinical data. JLS, CBPC and MHB wrote the main manuscript and MH8, ACM and CBPC edited the manuscript. JLS and ACM performed statistical analysis and reviewed the statistical analysis. All authors read and approved the final manuscript.

Funding

The authors declare that this study has received no financial support.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the institutional review board (Comitê de Ética em Pesquisa do Instituto Nacional de Cancer, CEP-INCA) and conducted in accordance with good clinical practice guidelines. Considering the observational retrospective design of the study, the institutional review board decided in favor of waiving the informed consent from all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflicts of interest.

Author details

1Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 2Gynecologic Oncology Section, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 3Division of Pathology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 4Immunology and Tumor Biology Program, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 5Vice-Presidency of Research and Biological Collections (VPPCB), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Received: 28 March 2021 Accepted: 17 November 2021 Published online: 07 December 2021

References

1. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bovilby R, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31(3):411–23.
2. Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137(3):581–8.
3. Gori I, Yanagibashi T, Taku A, Usagawa K, Miyaga E, Nakazawa T, et al. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer. 1997;72(5):821–7.
4. Gotloib O, Sugiyama Y, Takazawa Y, Kato K, Tanaka N, Omatu K, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019;10(1):4965.
5. El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin Obstet Gynecol. 2011;54(2):292–304.
6. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2010;20(5):888–94.
7. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98(1):176–86.
8. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immune’s roles in cancer suppression and promotion. Science. 2011;333(6024):1565–70.
9. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:185–98.
10. da Silva JL, Dos Santos ALS, Nunes NCC, de Moraes Lino da Silva F, CGM F, de Melo AC. Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol. 2019;84(2):227–40.
11. Francisco LM, Salinas VH, Brown KE, Vangui VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(3):3015–29.
12. Parousakis N, Duke-Cohan JS, Chaudhri A, Aksyloy H-L, Wang Q, Council A, et al. Interaction of SHP-2 SH2 domains with PD-1: IFNγ induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3(1):1–13.
13. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+T) cells. Sci Transl Med. 2013;5(200):200ra16.
14. Powell MA, Filici VL, Rose PG, Mannel RS, Hanjani P, Diegeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(16):2727–31.
15. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2009;105(2):109.
22. Matsuo K, Ross MS, Machida H, Blake EA, Roman LD. Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol. 2018;29(2) [cited 2020 Sep 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823963/.

23. Wallace AE, Gibson DA, Saunders PTK, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010;206(2):141–57.

24. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004;24(5C):3335–42.

25. Wallace AE, Sales KJ, Catalano RD, Anderson RA, Williams ARW, Wilson MR, et al. Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res. 2009;69(14):5726–33.

26. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol. 2008;109(2):216–21.

27. Levinson K, Dorigo O, Rubin K, Moore K. Immunotherapy in gynecologic cancers: what we know now and where we are headed. Am Soc Clin Oncol Educ Book. 2019; [cited 2020 Sep 9]. Available from: https://ascopubs.org/doi/pdf/10.1200/EDBK_237967.

28. Zhang S, Minaguchi T, Xu C, Qi N, Itagaki H, Shikama A, et al. PD-L1 and PD-1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas. BMC Cancer. 2020;20(1):127.

29. de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AGJ, Hollema H, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–10.

30. Jamyian T, Kuroda H, Yamaguchi R, Nakazato Y, Noda S, Onzoki M, et al. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative breast cancer. Breast Cancer. 2020;27(5):880–92.

31. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.

32. Ore-Arce M, Ballester CI, Lopez-Reig R, Parra-Grande M, Romero I, Lopez-Guerrero JA, et al. Clinicopathological significance and prognostic value of intratumoral and peritumoral lymphocytes in endometrial cancer patients. J Clin Oncol. 2019;37(15_suppl):e17116.

33. Sideras K, Galjart B, Vasaturo A, Pedroza-Gonzalez A, Biermann K, Mancham S, et al. Prognostic value of intra-tumoral CD8+/FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis. J Surg Oncol. 2018;118(1):68–76.

34. Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–85.

35. Heong V, Ngoi N, Tan DSP. Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol. 2017;28(2) [cited 2020 Sep 12]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC532387/.

36. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2590–20.

37. Chung HC, Ros W, Delord J-P, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(17):1470–8.

38. Engerud H, Berg HF, Myrvold M, Halle MK, Bjorge L, Haldorsen IS, et al. Significance of Lymphovascular space invasion by the Sarcomatous component in uterine Carcinosarcoma. Ann Surg Oncol. 2018;25(9):2756–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions